Form 4: Alector CEO Sells Shares for Tax Obligations

Alector, Inc. CEO Arnon Rosenthal sold 51,562 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Alector, Inc. CEO Arnon Rosenthal sold 51,562 shares of common stock on September 2, 2025.
• The shares were sold at a weighted average price of $2.4968, with individual transactions ranging from $2.30 to $2.59.
• The sale was conducted to satisfy tax obligations arising from the vesting of restricted stock units (RSUs).
• Following the transaction, Arnon Rosenthal directly beneficially owns 2,350,220 shares.
• Additionally, 150,000 performance share units (PSUs) were forfeited on May 6, 2025, due to the non-attainment of performance metrics.
• Indirect beneficial ownership includes 1,972,875 shares held by The Rosenthal Family Revocable Trust and 652,500 shares each held by the Adi Rosenthal 2007 Trust, Noam Rosenthal 2007 Trust, and Shani Rosenthal 2007 Trust.

Sentiment

Score: 4

Explanation: The sale for tax obligations is a neutral event. However, the forfeiture of 150,000 performance share units due to unmet metrics is a negative indicator for company performance, slightly outweighing the neutral nature of the tax-related sale.

Positives

• The reported sale of shares was explicitly for the purpose of satisfying tax obligations in connection with the vesting of restricted stock units, indicating it was not a discretionary sale based on a lack of confidence.

Negatives

• 150,000 performance share units (PSUs) were forfeited on May 6, 2025, because the associated performance metrics were not attained during the measurement period, indicating underperformance against internal targets.

Risks

• The forfeiture of 150,000 Performance Share Units (PSUs) suggests that certain internal performance targets were not met, which could signal underlying operational or financial challenges for the company.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the transaction details.

Industry Context

This Form 4 is a routine insider transaction filing, common in the biotechnology sector where executive compensation often includes equity awards. The sale for tax obligations is a standard practice and does not inherently signal a change in company fundamentals or broader industry trends. However, the forfeiture of PSUs could be a point of concern regarding internal performance targets, which is relevant in a highly competitive and R&D-intensive industry like biotech.

Comparison to Industry Standards

• Insider sales for tax purposes are a common occurrence across all industries, including biotechnology, and are generally not viewed as a negative signal.
• The forfeiture of performance-based equity awards, while not ideal, is also not uncommon if specific, often aggressive, performance milestones are not met within the biotechnology sector.
• Without specific performance metrics or industry benchmarks for Alector's peers, a direct comparison of the PSU forfeiture's significance is limited. However, it suggests that Alector may not have met certain internal growth or development targets that other comparable biotech firms might be achieving.

Stakeholder Impact

• Shareholders: The forfeiture of PSUs could raise questions about the company's ability to meet performance targets, potentially impacting investor confidence. The sale for tax purposes is a routine event and generally has minimal direct impact on shareholders beyond the change in insider ownership percentage.

Next Steps

• The filing does not specify any future actions, events, or milestones.

Key Dates

Recommendation

The Form 4 primarily details a routine insider stock sale to cover tax obligations, which is not inherently a positive or negative signal. However, the forfeiture of 150,000 performance share units due to unmet metrics is a minor negative, suggesting the company did not achieve certain internal targets. This information alone is insufficient to warrant a 'buy' or 'sell' recommendation, but it adds a slight cautionary note. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis and broader market context.

Keywords

Alector, ALEC, Insider Trading, Form 4, Stock Sale, CEO, Arnon Rosenthal, Restricted Stock Units, Performance Share Units, Tax Obligations, Biotechnology